CMP - Cipla Medpro South Africa Limited - Trading statement and clarification of

CMP - Cipla Medpro South Africa Limited - Trading statement and clarification of
results                                                                         
CIPLA MEDPRO SOUTH AFRICA LIMITED                                               
(Incorporated in the Republic of South Africa)                                  
(Registration number 2002/018027/06)                                            
(ISIN Number: ZAE000128179   Share Code: CMP)                                   
("Cipla Medpro" or "the Company")                                               
TRADING STATEMENT AND CLARIFICATION OF RESULTS                                  
In terms of the JSE Limited Listings Requirements, companies are required to    
publish a trading statement as soon as they are reasonably certain that the     
financial results for the current reporting period will be more than 20%        
different from those of the previous corresponding period.                      
Shareholders are advised that the Company expects earnings per share ("EPS")    
and headline earnings per share ("HEPS") for the six months ended 30 June 2011  
to be between 68% and 75% higher than the EPS and HEPS for the prior            
corresponding period.                                                           
The case against Pfizer Ltd and Pfizer Laboratories (Pty) Ltd, reported on      
SENS during October 2010, has been settled in our favour. This has positively   
affected the EPS and HEPS calculations but should be viewed as an isolated      
occurrence. The settlement income has been accounted for in our statement       
of comprehensive income however the terms thereof remain confidential. On a     
normalised basis, after adjusting for the settlement income received, the full  
effect of the fair value adjustment on the interest rate swaps, interest rate   
swap settlements and the forward exchange contract ("FEC") gains, normalised EPS
and HEPS are expected to increase between 20% and 27%.                          
The information in this trading statement has not been reviewed or reported on  
by Cipla Medpro`s auditors. The Company`s results for the six months ended 30   
June 2011 are expected to be published on or about 25 August 2011.              
11 August 2011                                                                  
Durban                                                                          
Investment Bank and Sponsor                                                     
Nedbank Capital                                                                 
Date: 11/08/2011 07:05:01 Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.